Cardinal Health initiated with a Neutral at Guggenheim. Guggenheim analyst Glen Santangelo initiated Cardinal Health with a Neutral rating and a price target of $51. The analyst says that while the company is “operating in a difficult environment in both its Pharmaceutical and Medical segments”, it is showing signs of stabilization operationally. Santangelo also warns however that Cardinal Health’s upside potential will be limited as long as investors are focused on the “potential for unfavorable regulatory change and the implications of the ongoing opioid litigation.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.